Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Expects 2023 Adjusted EBITDA of $74.0-$80.0 million
EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for the expanded clinical application of BRTX-100.
Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
FDA Addresses ‘Misinformation’ Concerning Delayed Approval Of Lucira Health’s COVID-19 & Flu Home Test
The FDA provided additional information about the agency’s interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc’s (OTC: LHDXQ)…
FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities
The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…
Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M
The deal covers the U.S., Canada, European Union, Great Britain, And Israel.
Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating
Reported Late Thursday March 9, MediciNova Announces Additional Extension Of BARDA Contract To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury; Contract Was Amended To Extend The Period Of Performance Until May 31, 2…
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with
Bill Gates Is Not Expecting You To Give Up Meat, Even Though The Planet Could Benefit From It — Here’s Why
In a lecture given last week at the fifth Ramnath Goenka Lecture in India, former Microsoft CEO and…